Abstract:BackgroundIt is necessary to differentiate high-risk human papillomavirus (HR-HPV) infection and cervical lesions during pregnancy using an effective measure, so as to guide personalized diagnosis and treatment and to reduce unnecessary invasive examinations during pregnancy.ObjectiveTo assess the value of HR-HPV E6/E7 mRNA detection in differentiating HR-HPV infection and cervical lesions during pregnancy by comparing efficacy between it and HR-HPV DNA testing.MethodsParticipants were healthy women with singleton pregnancy (20-45-years old) selected from Department of Obstetrics and Gynecology of Capital Medical University Xuanwu Hospital during January 2016 to January 2019. All had file creation and underwent regular prenatal examination, and those with abnormal liquid-based cytology and HR-HPV DNA testing results further underwent colposcopy with biopsy taken for pathological examination (serving as a gold standard) , and performed HR-HPV E6/E7 mRNA detection in cervical exfoliated cells collected as samples. Pathologically detected CIN Ⅱand Ⅲ were defined as high-grade cervical lesions.ResultsOf the 1 058 participants, 118 had cytological abnormalities and/or HPV 16 and 18 infections, and 84 of them consented to perform colposcopy with biopsy pathological results successfully obtained. The prevalence of HR-HPV E6/E7 mRNA positivity was lower than that of HR-HPV DNA positivity in women with CINⅠ, normal cervical epithelium or cervicitis detected by pathological examination (P<0.05) . In contrast, the prevalence of HR-HPV E6/E7 mRNA positivity was similar to that of HR-HPV DNA positivity in those with CINⅡ and Ⅲ detected by pathological examination without statistical difference (P>0.05) . In predicting CINⅡ and Ⅲ, the HR-HPV DNA testing had a sensitivity of 89.7% (26/29) , a specificity of 21.8% (12/55) , a positive predictive value of 37.1% (26/69) , and a negative predictive value of 75.0% (12/29) , and the HR-HPV E6/E7 mRNA detection had a sensitivity of 65.5% (19/29) , a specificity of 54.5% (25/55) , a positive predictive value of 43.0% (19/44) , and a negative predictive value 75.0% (25/40) . McNemar's test revealed that HR-HPV E6/E7 mRNA detection had a lower sensitivity but a higher specificity than HR-HPV DNA testing in diagnosing CINⅡ and Ⅲ (P<0.05) .ConclusionHR-HPV E6/E7 mRNA detection may have an increased specificity in diagnosing CINⅡandⅢ than HR-HPV DNA testing, so it may be used in HR-HPV positive cases for differentiating HR-HPV infections and cervical lesions to avoid unnecessary invasive examinations during pregnancy.

Human Papillomavirus (HPV) E6/E7 Mrna Detection in Cervical Exfoliated Cells: a Potential Triage for HPV-positive Women

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

The Value of MicroRNA-375 Detection for Triaging Primary Human Papillomavirus Positive Women: A Cross-Sectional Study in a General Population.

Clinical Value of Human Papillomavirus E6/E7 mRNA Testing in Patients with Atypical Squamous Cells of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion

HPV16 E7 oncoprotein test as a triage strategy for HPV16-positive women in cervical cancer screening: long-term follow-up outcome

HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up

MicroRNA Detection in Cervical Exfoliated Cells As a Triage for Human Papillomavirus-Positive Women.

Correlation analysis of human papillomavirus E6/E7 mRNA detection with diagnosis, prognosis and recurrence risk in patients with cervical epithelioma

Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.

Evaluation of HPV E6/E7 mRNA Detection in Clinically Suspected Cases of Cervical Cancer with Abnormal Cytology: Time to Upgrade the Screening Protocols

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology

Significance of high risk human papillomavirus E6/E7 mRNA in cervical cytology AS-CUS/LSIL/ASC-H

Preliminary study of the use of E6/E7mRNA detection in screening and triage management of HR-HPV infection during pregnancy

Risk Factors Triage on High-Risk Human Papillomavirus Testing Screening.

Clinical Evaluation of High-risk HR-HPV E6/E7 mRNA Detection during Pregnancy

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review

The Value of High-Risk HPV E6/E7 Mrna Test Positivity with NILM Cytology in Detecting Cervical Squamous Intraepithelial Lesions and Cervical Cancer

Do Women with High-Risk HPV E6/E7 Mrna Test Positivity and NILM Cytology Need Colposcopy?

Clinical Value of Branch-Dna Technique for Human Papillomavirus E6/E7 Mrna Detection in Cervical Lesions